医药巨头年末杀疯了：25亿美元买渐冻症药物，10.6亿美元ADC出海

Core Viewpoint - Shionogi plans to acquire the ALS drug business from Taro Pharmaceutical, which includes the oral suspension Radicava ORS and its intravenous formulation, aiming to enhance its rare disease commercialization platform in the U.S. market [1][3][10] Group 1: Acquisition Details - The transaction is expected to close on or after April 1, 2026, and will add approximately $700 million in global sales annually for Shionogi [3][10] - Shionogi will pay a one-time fee of $2.5 billion for the Radicava-related business, with potential future royalties contingent on specific conditions [3][10] - Post-acquisition, the Radicava business unit will operate as a wholly-owned subsidiary of Shionogi [3][10] Group 2: Strategic Importance - The acquisition will support Shionogi's plans to launch drugs for Fragile X syndrome, Jordan's syndrome, and Pompe disease [3][10] - Radicava's intravenous formulation was approved by the FDA in 2017, marking it as the first new ALS treatment in decades, and the oral formulation was approved five years later, providing a more convenient treatment option for patients [3][10] Group 3: Industry Context - Shionogi has been active in the M&A market, recently acquiring early-stage rare disease assets from Japan Tobacco and collaborating with Swiss biotech company BioVersys for a preclinical antibiotic project [3][10] - On the same day, Ipsen and Ascendia announced an exclusive licensing agreement for ADC SIM0613, highlighting the ongoing consolidation in the global pharmaceutical industry [3][12][14]